High doses of vitamin D may benefit patients with metastatic colorectal cancer by slowing the progression of the disease

Recently, scientists from Dana Faber Cancer Institute in the United States conducted a small clinical trial (http://www.chemdrug.com/sell/24/) and found that high-dose vitamin D supplementation in the chemotherapy process can benefit the patients with metastatic colorectal cancer by slowing down the progress of the disease This is the first randomized clinical trial completed by researchers to analyze (http://www.chemdrug.com/sell/76/) benefits of vitamin D supplementation in patients with malignant or metastatic prostate cancer The research is published in the international journal JAMA   In the high-dose group, life expectancy was delayed by 13 months before the disease worsened, while in the low-dose group, life expectancy was delayed by 11 months, the researchers said In addition, in the 22.9-month study, patients in the high-dose group were 36% less likely to progress or die, so the number of patients in this clinical trial was small, so the researchers It is not certain that patients receiving high doses of vitamin D have improved overall survival In phase 2 clinical trials, researchers wanted to pass the study test (http://www.chemdrug.com/sell/76/) Whether vitamin D supplementation can improve the prognosis of patients with metastatic colorectal cancer, all patients were treated with standard chemotherapy system (mfolfox6 + bevacizumab), high-dose vitamin D intake group began to take 8000IU of vitamin D every day for 14 days, then 4000iu of vitamin D every day, while low-dose intake group took 400IU of vitamin D every day during the whole study During the course of the study, all participants were asked if they would take additional vitamin D or calcium supplements The researchers also measured 25 hydroxyvitamin D levels in patients' blood samples, which can reflect the body's vitamin D intake The researchers said that during the whole research process, there was no significant change in the vitamin D level of individuals in the low-dose vitamin D intake group, while the individuals in the high-dose vitamin D intake group soon reached a sufficient range of vitamin D and could maintain the level all the time Moreover, obese patients and patients with KRAS mutations in body tumors seem to benefit less from high doses of vitamin D These studies suggest that patients with specific subgroups may also need higher doses of vitamin D to fight cancer.